Previous 10 | Next 10 |
2024-02-07 10:00:01 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Lilly, Zoetis, Abbott least shor...
A look at the top 10 most actives in the United States Palantir Technologies Inc. Class A (PLTR) rose 30.8% to $21.87 on volume of 421,271,485 shares InVivo Therapeutics Holdings Corp. (NVIV) rose 136.9% to $0.526 on volume of 188,439,590 shares New York Community Bancorp Inc. (NYCB) fell...
EQ101 Phase 2 study in alopecia areata is fully enrolled with topline data expected in Q2 2024 EQ302, an orally delivered multi-cytokine inhibitor of IL-15 & IL-21, will be advanced in place of further clinical development of EQ102 based on EQ302’s optimal delivery and increase...
EQ Bank Card launches in Québec as Carte Banque EQ Canada NewsWire Popular bank card gives customers the ability to earn, save, and spend their money TORONTO , Nov. 20, 2023 /CNW/ - EQ Bank (Banque EQ in Québec) is offering Québec customers...
Revenue Increases Over 24% Year Over Year - Adjusted EBITDA on Track to Profitability TORONTO, ON / ACCESSWIRE / November 16, 2023 / EQ Inc. (TSXV:EQ) ("EQ", "EQ Works" or the "Company"), a leader in AI and geospatial data driven software and solutions, announced its financial results today ...
Itolizumab continues to show clinically meaningful response in highly proteinuric subjects At Week 28, 73% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR) Itolizumab demonstrated a favorable safety and tolerability profile Equillium , ...
Equillium Inc. (EQ) is expected to report $-0.16 for Q3 2023
2023-11-08 17:32:06 ET More on Equillium Seeking Alpha’s Quant Rating on Equillium Historical earnings data for Equillium Financial information for Equillium For further details see: Equillium GAAP EPS of -$0.11 beats by $0.05, revenue of $8.87M be...
$46.3 million in cash at the end of Q3 2023 expected to provide operating runway into 2025 $1.9 million of cash used in operating activities in Q3 2023 Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to d...
Itolizumab continues to show clinically meaningful response in highly proteinuric subjects At Week 28, 73% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR) Itolizumab demonstrated a favorable safety and tolerability profile Equillium , ...
News, Short Squeeze, Breakout and More Instantly...
Equillium Inc. Company Name:
EQ Stock Symbol:
NASDAQ Market:
$32.3 million cash balance at the end of Q1 2024 expected to provide cash runway into 2H 2025 Announced positive topline data from Phase 1b EQUALISE study of itolizumab in lupus nephritis patients, representing the first of two data sets that will trigger Ono Pharmaceutical’s optio...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Positive EBITDA and quarterly revenue increased by 19% TORONTO, ON / ACCESSWIRE / April 15, 2024 / EQ Inc. (TSXV:EQ.V) ("EQ Works" or the "Company"), a leader in AI and data driven software and solutions, announced its financial results today for the fourth quarter and the year ended Decembe...